Cell death modulation by intravenous immunoglobulin
- PMID: 20405180
- DOI: 10.1007/s10875-010-9411-8
Cell death modulation by intravenous immunoglobulin
Abstract
The induction of cell death in immune cells by naturally occurring antibodies specific for death receptors may present an important antiinflammatory mechanism of intravenous immunoglobulin (IVIG). Conversely, the protection of tissue cells from death receptor-mediated apoptosis by blocking antibodies is thought to contribute to the beneficial effects of IVIG in certain inflammatory disorders such as toxic epidermal necrolysis, also known as Lyell's syndrome. In this review, we focus on recent insights into the role of functional antibodies against Fas, sialic acid-binding immunoglobulin-like lectin (Siglec)-8, and Siglec-9 receptors in IVIG-mediated cell survival or death effects. In addition, we examine a variety of factors in inflammatory disease that may interplay with these cellular events and influence the therapeutic efficacy or potency of IVIG. These involve activation status of the target cell, cytokine microenvironment, pathogenesis and stage of disease, individual genetic determinants, species characteristics, and batch-to-batch variations of IVIG preparations.
Similar articles
-
Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies.J Allergy Clin Immunol. 2007 Apr;119(4):1005-11. doi: 10.1016/j.jaci.2007.01.023. Epub 2007 Mar 2. J Allergy Clin Immunol. 2007. PMID: 17337295
-
Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).Autoimmun Rev. 2008 Jun;7(6):453-6. doi: 10.1016/j.autrev.2008.03.015. Epub 2008 Apr 18. Autoimmun Rev. 2008. PMID: 18558361 Review.
-
Dimeric IVIG contains natural anti-Siglec-9 autoantibodies and their anti-idiotypes.Allergy. 2011 Aug;66(8):1030-7. doi: 10.1111/j.1398-9995.2011.02579.x. Epub 2011 Mar 9. Allergy. 2011. PMID: 21385183
-
Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.J Allergy Clin Immunol. 2003 Dec;112(6):1185-90. doi: 10.1016/j.jaci.2003.09.045. J Allergy Clin Immunol. 2003. PMID: 14657880
-
Siglec-8 and Siglec-F, the new therapeutic targets in asthma.Immunopharmacol Immunotoxicol. 2012 Oct;34(5):721-6. doi: 10.3109/08923973.2011.589453. Epub 2012 Feb 11. Immunopharmacol Immunotoxicol. 2012. PMID: 22324980 Review.
Cited by
-
FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity.Nat Commun. 2021 Aug 9;12(1):4791. doi: 10.1038/s41467-021-24591-x. Nat Commun. 2021. PMID: 34373452 Free PMC article.
-
Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells.Front Immunol. 2017 Jun 16;8:697. doi: 10.3389/fimmu.2017.00697. eCollection 2017. Front Immunol. 2017. PMID: 28670314 Free PMC article.
-
Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs.Front Immunol. 2023 Mar 28;14:1166821. doi: 10.3389/fimmu.2023.1166821. eCollection 2023. Front Immunol. 2023. PMID: 37063852 Free PMC article. Review.
-
IVIG regulates the survival of human but not mouse neutrophils.Sci Rep. 2017 May 2;7(1):1296. doi: 10.1038/s41598-017-01404-0. Sci Rep. 2017. PMID: 28465620 Free PMC article.
-
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.J Clin Invest. 2014 Apr;124(4):1810-20. doi: 10.1172/JCI65899. Epub 2014 Feb 24. J Clin Invest. 2014. PMID: 24569453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous